The consensus among analysts is that Lipocine Inc. (LPCN) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 1 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.07.

Lipocine Inc. (LPCN) estimates and forecasts

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +20.6% over the past 5 years. Earnings growth for 2020 is a modest +8% while over the next 5 years, the company’s earnings are expected to increase by 0%.

Lipocine Inc. (NASDAQ:LPCN)’s Major holders

Insiders own 3.68% of the company shares, while shares held by institutions stand at 17.76% with a share float percentage of 18.44%. Investors are also buoyed by the number of investors in a company, with Lipocine Inc. having a total of 34 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 1.07 Million shares worth more than $511.87 Thousand. As of March 30, 2020, Vanguard Group, Inc. (The) held 2.23% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 805.44 Thousand shares as of March 30, 2020. The firm’s total holdings are worth over $386.61 Thousand and represent 1.68% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of March 30, 2020, the former fund manager holds about 1.29% shares in the company for having 618404 shares of worth $296.83 Thousand while later fund manager owns 406.01 Thousand shares of worth $194.88 Thousand as of March 30, 2020, which makes it owner of about 0.85% of company’s outstanding stock.